Emend Recall

Get an alert when a recall is issued.

Questions & Answers

Side Effects & Adverse Reactions

There is currently no warning information available for this product. We apologize for any inconvenience.

Legal Issues

There is currently no legal information available for this drug.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.


1.1 Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)

EMEND, in combination with other antiemetic agents, is indicated for the:

  • prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin
  • prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) [see Dosage and Administration (2.1)].
1.2 Prevention of Postoperative Nausea and Vomiting (PONV)

EMEND is indicated for the prevention of postoperative nausea and vomiting [see Dosage and Administration (2.2)].

1.3 Limitations of Use

EMEND has not been studied for the treatment of established nausea and vomiting.

Chronic continuous administration is not recommended [see Warnings and Precautions (5.5)].


There is currently no drug history available for this drug.

Other Information

EMEND (aprepitant) is a substance P/neurokinin 1 (NK1) receptor antagonist, chemically described as 5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one.

Its empirical formula is C23H21F7N4O3, and its structural formula is:

image of chemical structure

Aprepitant is a white to off-white crystalline solid, with a molecular weight of 534.43. It is practically insoluble in water. Aprepitant is sparingly soluble in ethanol and isopropyl acetate and slightly soluble in acetonitrile.

Each capsule of EMEND for oral administration contains either 40 mg, 80 mg or 125 mg of aprepitant and the following inactive ingredients: sucrose, microcrystalline cellulose, hydroxypropyl cellulose and sodium lauryl sulfate. The capsule shell excipients are gelatin, titanium dioxide, and may contain sodium lauryl sulfate and silicon dioxide. The 40‑mg capsule shell also contains yellow ferric oxide, and the 125‑mg capsule also contains red ferric oxide and yellow ferric oxide.

Emend Manufacturers

  • Physicians Total Care, Inc.
    Emend (Aprepitant) Capsule Emend (Aprepitant) Kit [Physicians Total Care, Inc.]
  • Rebel Distributors Corp
    Emend (Aprepitant) Capsule [Rebel Distributors Corp]
  • Merck Sharp & Dohme Corp.
    Emend (Aprepitant) Capsule Emend (Aprepitant) Kit [Merck Sharp & Dohme Corp.]
  • Merck Sharp & Dohme Corp.
    Emend (Fosaprepitant Dimeglumine) Injection, Powder, Lyophilized, For Solution [Merck Sharp & Dohme Corp.]

Login To Your Free Account